NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM

BACKGROUND: Plexiform neurofibromas (PNs) can cause significant morbidity. In this phase 2 study, we assessed imaging and functional outcomes to the MEK-inhibitor Binimetinib in pediatric patients with PNs. METHODS: Children (age 1–17 years) with PN that were progressive or causing significant morbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Sabine, Reddy, Alyssa T, Dombi, Eva, Allen, Jeffrey, Packer, Roger, Clapp, Wade, Goldman, Stewart, Schorry, Elizabeth, Tonsgard, James, Blakeley, Jaishri, Ullrich, Nicole J, Gross, Andrea, Walsh, Karin, Thomas, Coretta, Edwards, Lloyd, Prados, Michael, Korf, Bruce, Fisher, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Neurofibromatosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715338/
http://dx.doi.org/10.1093/neuonc/noaa222.619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715338/
http://dx.doi.org/10.1093/neuonc/noaa222.619

Ejemplares similares